In our final Drug Injury Watch article for 2020 we want to report on the recent developments regarding Elmiron lawsuits, Elmiron side effects warnings, and Elmiron pigmentary maculopathy diagnosis methods.
As regards the increasing number of Elmiron lawsuits for patients who have suffered vision loss due to Elmiron pigmentary maculopathy, there is now a federal court Elmiron MDL consolidation. On December 15, 2020, this JPML Order, “IN RE: ELMIRON (PENTOSAN POLYSULFATE SODIUM) PRODUCTS LIABILITY LITIGATION – MDL No. 2973“, was issued. The Elmiron MDL has been assigned to Judge Brian R. Martinotti for coordinated or consolidated proceedings, and all current Elmiron lawsuits filed in the U.S. federal court system will be transferred to the District of New Jersey.
Turning to Elmiron side effects warnings developments, on December 15, 2020, a Dear Healthcare Professional Letter titled, “ELMIRON (pentosan polysulfate sodium) and the Risk of Pigmentary Maculopathy”, was issued in Canada by Janssen, Inc. and Health Canada. Its key messages were: (1) Cases of Elmiron pigmentary maculopathy have been reported with long-term use of Elmiron; and (2) Elmirion is now contraindicated in patients with a previous history of any macular pathology.
Lastly, there is some new information about Elmiron pigmentary maculopathy diagnosis methods. A December 22, 2020, medical article, “From Bladder Pain to Blurry Vision: Pentosan Polysulfate Sodium and the Development of a Novel Maculopathy”, published in Ophthalmic Surgery, Lasers and Imaging Retina, discusses the symptoms of pigmentary maculopathy as well as how doctors might diagnose this serious eye disease which may lead to significant vision loss.
Our law firm is investigating possible Elmiron lawsuits for patients who have suffered vision loss due to Elmiron pigmentary maculopathy. If we can be of assistance to you or someone else regarding an Elmiron vision loss case, you can submit an online Elmiron Case Evaluation Form or you can call us on our toll-free number: 800-426-9535.[Read article in full at original source]